Literature DB >> 10450273

Clozapine-associated elevation in serum triglycerides.

B D Gaulin1, J S Markowitz, C F Caley, L A Nesbitt, R L Dufresne.   

Abstract

OBJECTIVE: This study was conducted to determine serum lipid level changes in patients who received clozapine or haloperidol.
METHOD: Medical records of 222 inpatients treated with clozapine or haloperidol were reviewed. Age, weight, gender, daily antipsychotic dose, total cholesterol level, serum triglyceride level, and concurrent medications were recorded.
RESULTS: Clozapine-treated men had significantly higher follow-up serum triglyceride concentrations over baseline than did haloperidol-treated men. Female patients experienced serum triglyceride level elevations regardless of antipsychotic treatment. Changes in total cholesterol levels were not significantly different between treatment groups.
CONCLUSIONS: An increase in serum triglyceride levels occurred in clozapine-treated patients; screening for serum triglyceride elevations may be warranted before treatment with clozapine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450273     DOI: 10.1176/ajp.156.8.1270

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

Review 1.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

2.  Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder.

Authors:  Jess G Fiedorowicz; David A Solomon; Jean Endicott; Andrew C Leon; Chunshan Li; John P Rice; William H Coryell
Journal:  Psychosom Med       Date:  2009-06-26       Impact factor: 4.312

Review 3.  Generic clozapine: a cost-saving alternative to brand name clozapine?

Authors:  Gordon Tse; Deborah Thompson; Ric M Procyshyn
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Cardiovascular morbidity and mortality in bipolar disorder.

Authors:  Miriam Weiner; Lois Warren; Jess G Fiedorowicz
Journal:  Ann Clin Psychiatry       Date:  2011-02       Impact factor: 1.567

Review 5.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

7.  Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.

Authors:  Johan Fernø; Audun O Vik-Mo; Goran Jassim; Bjarte Håvik; Kjetil Berge; Silje Skrede; Oddrun A Gudbrandsen; Jo Waage; Niclas Lunder; Sverre Mørk; Rolf K Berge; Hugo A Jørgensen; Vidar M Steen
Journal:  Psychopharmacology (Berl)       Date:  2008-10-30       Impact factor: 4.530

Review 8.  Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Authors:  Michael Berk; Joanna Fitzsimons; Timothy Lambert; Christos Pantelis; Jayashri Kulkarni; David Castle; Elizabeth W Ryan; Sean Jespersen; Pat McGorry; Gregor Berger; Bill Kuluris; Tom Callaly; Seetal Dodd
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.

Authors:  K I Melkersson; M-L Dahl
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530

Review 10.  Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.

Authors:  K I Melkersson; M-L Dahl; A-L Hulting
Journal:  Psychopharmacology (Berl)       Date:  2004-06-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.